论文部分内容阅读
2012年,经过药品审评中心的审评,提出建议批准以下多个重要治疗领域的药品,为患者获得最新治疗手段提供了可能性,为患者用药可及性及可支付性提供了重要保证。1抗艾滋病药物(HIV)领域针对HIV耐药以及增加治疗的顺应性方面,今年提供了以下与全球同步的、最新的治疗手段。1.1利匹韦林片(批准文号:H20120561),是一种二苯胺嘧啶衍生物,属于新型的非核苷类逆转录酶抑制剂(NNRTl),具有很强的抗野生型HIV-1和耐药突变株活性。对耐药的HIV患者具有治疗作用。FDA批准时间2011年5月。2012年我国批准该药品上市,使
In 2012, after review by the Center for Drug Evaluation, recommendations were made for the approval of medicines in several key areas of treatment that provided the patient with access to up-to-date treatment and provided an important guarantee for patient access and affordability. 1 In the field of anti-HIV drug (HIV), the following globally-synchronized and up-to-date treatment methods are provided for HIV resistance and to increase compliance with treatment this year. 1.1 Lipivirin tablet (approval number: H20120561), is a diphenylamine pyrimidine derivative, belongs to the new non-nucleoside reverse transcriptase inhibitor (NNRTl), has a strong anti-wild-type HIV-1 and resistance Mutant activity. Resistant to HIV patients have a therapeutic effect. FDA approval date May 2011. In 2012 our country approved the drug market, so